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Abstract:
Background: Most women are prescribed an opioid after hysterectomy. 
The objective of this study was to determine the association between 
initial opioid prescribing characteristics and chronic opioid use after 
hysterectomy. 
Methods: This study included women enrolled in a commercial health 
plan who had a hysterectomy between July 01, 2010 and March 31, 
2015. We used trajectory models to define chronic opioid use as patients 
with the highest probability of having an opioid prescription filled during 
the 6 months post-surgery. We used multivariable logistic regression to 
examine the association between initial opioid dispensing (amount 
prescribed and duration of treatment) and chronic opioid use after 
adjusting for potential confounders. 
Results: A total of 693 of 50,127 (1.38%) opioid naïve women met the 
criteria for chronic opioid use following hysterectomy. The baseline 
variables and initial opioid prescription characteristics predicted the 
pattern of long-term opioid use with moderate discrimination (c statistic 
= 0.70). Significant predictors of chronic opioid use included initial opioid 
daily dose (≥60 MME vs < 40 MME, aOR: 1.43, 95%CI: 1.14-1.79), and 
days’ supply 4-7 days vs 1-3 days, aOR: 1.28, 95%CI: 1.06-1.54; ≥8 
days vs 1-3 days, aOR: 1.41, 95%CI: 1.05-1.89). Other significant 
baseline predictors included older age, abdominal or laparoscopic/robotic 
hysterectomy, tobacco use, psychiatric medication use, back pain, and 
headache. 
Conclusion: Initial opioid prescribing characteristics are associated with 
risk of chronic opioid use after hysterectomy. Prescribing lower daily 
doses and shorter days’ supply of opioids to women after hysterectomy 
http://mc.manuscriptcentral.com/pds
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may result in lower risk of chronic opioid use.  
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Abstract
Background: Most women are prescribed an opioid after hysterectomy. The objective of this 
study was to determine the association between initial opioid prescribing characteristics and 
chronic opioid use after hysterectomy. 
Methods: This study included women enrolled in a commercial health plan who had a 
hysterectomy between July 01, 2010 and March 31, 2015. We used trajectory models to define 
chronic opioid use as patients with the highest probability of having an opioid prescription filled 
during the 6 months post-surgery. We used multivariable logistic regression to examine the 
association between initial opioid dispensing (amount prescribed and duration of treatment) and 
chronic opioid use after adjusting for potential confounders. 
Results: A total of 693 of 50,127 (1.38%) opioid naïve women met the criteria for chronic opioid 
use following hysterectomy. The baseline variables and initial opioid prescription characteristics 
predicted the pattern of long-term opioid use with moderate discrimination (c statistic = 0.70). 
Significant predictors of chronic opioid use included initial opioid daily dose (≥60 MME vs < 40 
MME, aOR: 1.43, 95%CI: 1.14-1.79), and days’ supply 4-7 days vs 1-3 days, aOR: 1.28, 
95%CI: 1.06-1.54; ≥8 days vs 1-3 days, aOR: 1.41, 95%CI: 1.05-1.89). Other significant 
baseline predictors included older age, abdominal or laparoscopic/robotic hysterectomy, 
tobacco use, psychiatric medication use, back pain, and headache.
Conclusion: Initial opioid prescribing characteristics are associated with risk of chronic opioid 
use after hysterectomy. Prescribing lower daily doses and shorter days’ supply of opioids to 
women after hysterectomy may result in lower risk of chronic opioid use.  
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Introduction
The rapid increase in the incidence of opioid-related overdoses and deaths has become 
a major public health crisis in the United States. Overdose and death from prescription opioid 
overdose increased 400% in women between 1999 and 2013.1-3 For many women, their first 
exposure to prescription opioids often occurs during the post-operative period, which makes this 
a potential target for strategies to reduce the risk of chronic opioid use.4-6 Several observational 
studies suggest that surgery is a risk factor for chronic opioid use.5-18 Two studies have 
examined the relationship between the initial opioid prescribing characteristics and chronic 
opioid use in the postoperative setting and arrived at contradictory conclusions.6,12 One study 
reported that initial exposure to prescription opioids after minor surgery increases the risk of 
chronic opioid use by 44%,12 while the other suggested that the initial opioid prescribing 
characteristics, including type of opioid dispensed, days’ supply, or daily dose (in morphine 
milligram equivalents), were not associated with chronic opioid use after cesarean delivery.6 
Hysterectomy, the most commonly performed non-obstetric surgery among women in 
the United States,19-21 poses a potential risk for chronic opioid use because an estimated 82% of 
patients receive an opioid prescription after the hysterectomy surgery.20,22 However, the 
relationship between the initial opioid prescribing characteristics and chronic opioid use after 
hysterectomy remains largely unknown. The objective of this study was to identify baseline risk 
factors for chronic opioid use after hysterectomy and examine the association between initial 
opioid prescribing characteristics after hysterectomy and subsequent chronic use of opioids 
among opioid naïve women.
Methods
Data Sources: Study data were derived from the national OptumInsight Clinformatics Data 
MartTM (OptumInsight, Eden Prairie, MN). The Optum Clinformatics Data Mart is an 
administrative health claims database from a large national insurer which includes 
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approximately 35 million beneficiaries. The dataset contains transactional reimbursement data 
for health care utilization including outpatient pharmacy dispensing, and inpatient and outpatient 
medical claims.23 The administrative enrollment file has eligibility information, the outpatient 
pharmacy file has the national drug code (NDC) for each drug dispensed, and the medical files 
have the Current Procedural Terminology (CPT) code for medical procedure, and International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for medical 
procedure and diagnosis. Patients included in the database had both medical and prescription 
coverage. The data was used under license agreement between the University of Rhode Island 
and OptumInsight Inc. 
Study Population: This study included women (≥ 18 years) who had a hysterectomy between 
July 01, 2010 and March 30, 2015. Women were required to have at least 6 months of 
continuous enrollment prior to hysterectomy. To identify an opioid-naïve study cohort, we 
excluded women with a diagnosis of opioid use disorders or any opioids filled 6 months before 
the date of the hysterectomy (index date) (eTable 1). The hysterectomy procedures were 
identified using ICD-9-CM procedure and CPT codes from both the inpatient and outpatient 
claims (eTable 1).21,24 We excluded patients who had a radical hysterectomy and patients for 
whom we could not rule-out a cancer diagnosis which was defined as ≥ 2 separate medical 
claims with a cancer diagnosis occurred ≥42 days apart or receipt of chemotherapy, radiation, 
or other cancer-related surgery (eTable 1).25 Women who filled at least one opioid prescription 
at a retail pharmacy within 7 days of discharge were considered exposed to prescription opioids 
and included in the final study cohort. The 7-day window was based on the assumption that an 
opioid prescription filled by an opioid naïve individual during this period was likely used to treat 
acute pain after hysterectomy. This study was approved by the University of Rhode Island 
Institutional Review Board (IRB#957873-2). 
Exposure to opioids: Opioid prescriptions were identified using national drug codes (NDC) 
from the outpatient pharmacy claims. Opioid prescriptions were classified as hydrocodone, 
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oxycodone and others (including codeine, fentanyl, hydromorphone, meperidine, morphine, 
pentazocine, tapentadol, and tramadol). Duration of the initial prescription was categorized as 1-
3, 4-7, ≥ 8 days. We calculated the morphine milligram equivalent (MME) for the initial opioid 
prescription using the Center for Disease Control (CDC) conversion Tables (2016 version). The 
average daily MME dose was categorized into tertiles (≤40mg/day, 40.50-58.9mg/day, and 
≥60mg/day). 
Outcome Assessment: We used trajectory models to generate our dichotomous primary study 
outcome as chronic opioid use after hysterectomy present or absent.11 The trajectory models 
allow the use of observed longitudinal data to determine distinct opioid prescription filling 
patterns in the study population during the six months period after hysterectomy. This approach 
classifies patients into groups with similar opioid prescription filling patterns during follow-up 
without relying on a prespecified cutoff value for the definition of chronic opioid use.26,27 In order 
to classify the trajectory groups for opioid use during the defined follow-up window (6 months 
after hysterectomy), we first generated 6 dichotomous variables to indicate if a study participant 
filled a prescription of an opioid analgesic during each of 6 consecutive 30-day follow-up 
periods, e.g., month 1 is from 7 to 37 days, month 2 is from 37 to 67 days, and month 6 is from 
157 to 187 days.11 We then modeled these 6 binary indicators of opioid use in each 30-day 
follow-up period as a longitudinal response in a logistic group-based trajectory.28,29 Using the 
trajectory model, we estimated the probability of membership of patients in each group, and the 
probability of filling an opioid prescription over time as a smooth function of time. The model was 
fitted using 2 to 5 opioid exposure groups and the number of groups was chosen based on the 
value of the Bayesian Information Criterion.30 In each group, a third-order polynomial (including 
linear, squared, and cubic terms) of time were used to model the probability of filling a 
prescription for opioids. Patients were assigned to the trajectory group in which they had the 
highest probability of membership. Based on the model results, the trajectory group with the 
highest probability of filling any opioid prescription beyond the initial prescription was defined as 
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“chronic opioid users”. All other trajectory groupings were classified as non-chronic opioid users. 
The percentage of patients who filled an opioid prescription was reported in each trajectory for 
every consecutive 30-day follow-up period. 
Potential Predictors of Chronic Opioid Use: We collected data on potential confounding 
variables that may be related to both initial opioid prescribing characteristics and chronic opioid 
use after hysterectomy.6-11,31 Previous studies demonstrated that age, certain pain conditions, 
and psychiatric disorders are associated with both postsurgical chronic pain and chronic 
prescription opioid use.6,21,31-36 Covariates assessed  in our analyses included age at 
hysterectomy, Charlson comorbidity index, hospital length of stay, smoking status, use of 
alcohol and illicit substances, psychiatric medication use, pre-operative pain conditions, types of 
hysterectomy procedure performed, US census region, type of insurance (Medicare or private 
insurance) and health plan (exclusive provider organization, health maintenance organization, 
point of service, and others including indemnity and preferred provider organization), year of 
surgery, and initial opioid prescribing characteristics (medication type, average daily dose, and 
number of days’ supplied).
Statistical Analysis: Categorical variables were examined and compared using Chi-squared or 
Fisher exact tests. Continuous variables were compared using the student t test. Statistical tests 
and modeling were conducted to identify risk factors for chronic opioid use among women after 
hysterectomy. A multivariable logistic regression model was used to estimate the association 
between baseline demographic and clinical variables, initial opioid prescribing characteristics, 
and chronic opioid use after hysterectomy among opioid-naive patients who filled at least one 
opioid prescription within 7 days after hysterectomy. 
Sensitivity studies were conducted using multivariate logistic regression models to 
examine if the significant association between initial prescribing pattern and subsequent chronic 
opioid use were upheld with a different definition of chronic opioid use post hysterectomy or a 
more restricted definition for opioid naivety after adjusting for other covariates. 
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A probability of type 1 error (alpha) = 0.05 was set as the threshold of statistical 
significance. The trajectory models were conducted using “Proc Traj”. All statistical analyses 
were performed using Statistical Analysis Software (SAS), version 9.4 (SAS Institute Inc, 
Cary, NC). 
Results
Study cohort: A total of 157,934 women underwent hysterectomy between 07/01/2010 and 
03/31/2015. Of these patients, 22,186 (14%) patients did not meet the continuous enrollment 
criteria, 14,696 (9%) had suspected cancer diagnoses or radical hysterectomy, 18,202 (12%) 
didn’t fill an opioid prescription within 7 days of surgery, 3,918 (2%) were missing important 
demographic data, 48,778 (31%) used opioids in the 6 months prior to surgery and 232 (0.1%) 
were diagnosed with OUD within 6 months prior to hysterectomy, leaving 50,127 (32%) patients 
for the analysis.  A total of 12,985 (26%) pat ents had an abdominal hysterectomy; 29,640 
(59%) patients had a laparoscopic or robotic assisted laparoscopic hysterectomy; and 7,502 
(15%) patients had a vaginal hysterectomy (Figure 1).
The trajectory model identified 4 distinct trajectories of prescription opioid use after 
hysterectomy, with total 39,677 (79.15%) patients in trajectory 1, 3,304 (6.59%) in trajectory 2, 
6,453 (12.87%) in trajectory 3, and 693 (1.38%) in trajectory 4. (Figure 2). Among the patients in 
trajectory 4 (n=693, 1.38%), 57%, 55%, 57%, 55%, 48%, and 41% filled an opioid prescription 
at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months following an initial 
prescription in the 7 days post-hysterectomy, respectively.  Patients in trajectory 4 were 
classified as chronic opioid users. No patient in trajectory 1 (n=39,677, 79.15%) filled any opioid 
prescription (0%) from month 1 to 6. Among patients in trajectory 2 (n=3,304, 6.59%), 0.3% 
filled a prescription at month 1, which increased to 2.6% at month 2, 8% at month 3, and then 
followed by 10% with opioid fills for the subsequent 3 months. Thirty-five percent of patients in 
trajectory 3 (n=6,543, 12.87%) filled an opioid prescription at month 1, which decreased to 8% 
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at month 2, and then gradually decreased to  4% at month 3, and  3% at months 4, 5, and 6. A 
description of the demographic and clinical characteristics of the patients assigned to each of 
these 4 trajectories is included in eTable2. 
Characteristics of patients and initial prescriptions: Among the total 50,127 opioid naïve 
patients who filled at least one opioid prescription within 7 days after hysterectomy, 693 (1.38%) 
patients were categorized as chronic opioid users and 48,434(98.62%) were categorized as 
non-chronic users. Baseline characteristics among chronic opioid users after hysterectomy were 
significantly different from non-chronic opioid users (Table 1). Compared to the women without 
chronic opioid use, women with chronic opioid use were older and more likely to have a history 
of tobacco use, and a history of alcohol use. Chronic opioid users also were also more likely to 
be taking psychiatric medications, including benzodiazepines, antidepressants, and stimulants. 
Back pain and headache syndromes were more prevalent in the chronic opioid use group. 
Compared to women with commercial insurance, women with Medicare insurance had higher 
rates of chronic opioid use. About 1.5 percent of Medicare patients who were chronic opioid 
users after hysterectomy were younger than 65. 
In unadjusted analyses, the average daily MME/day and the type of the initial opioid 
prescription were similar between women categorized as having chronic use and not having 
chronic opioid use. The days’ supplied of the initial opioid was marginally greater among chronic 
users than for non-chronic users (5.12 versus 4.85 days, respectively, p = 0.02) (Table 1). 
Overall, oxycodone was more frequently prescribed hydrocodone or other opioids. 
Predictors of chronic opioid use among all patients in the study: The results of 
multivariable logistic regression analyses are shown in Table 2. A number of factors were 
significantly associated with chronic opioid use after hysterectomy including older age, 
abdominal or laparoscopic/robotic hysterectomy, Charlson comorbidity index, tobacco use, 
alcohol use, and prescribed psychotropic medications. Pain conditions, including headache 
syndromes and back pain at baseline, were also identified as significant risk factors for chronic 
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opioid use after hysterectomy. Health plan type, census region, surgical setting, fibromyalgia, 
and other substance use disorders were not included in the final multivariable analyses due to 
lack of significance.  
The characteristics of the initial opioid prescription, including type of opioid dispensed, 
days’ supply, and daily dose in MME, were fitted in the model. Among initial opioid prescribing 
characteristics, significant predictors of chronic opioid use were initial prescription of 
hydrocodone (compared to oxycodone, aOR: 1.31, 95%CI: 1.10-1.57), days’ supply (4-7 days 
vs ≤3 days, aOR: 1.28, 95%CI: 1.06-1.54; ≥8 days vs ≤ 3 days, aOR: 1.41, 95%CI: 1.05-1.89), 
and daily dose in MME (≥60 mg/day vs ≤40 mg/day, aOR: 1.43, 95%CI: 1.14-1.79), The C-
statistic for the fitted full model was 0.70, indicating moderate predictability (Table 2)
The frequencies of post-surgery complications and other conditions associated with pain 
during the 6-month follow-up were examined in the study cohort (Table 3). Compared with non-
chronic opioid users, women who developed chronic opioid use after hysterectomy were more 
frequently diagnosed with chronic pancreatitis, headache syndrome, back pain, fibromyalgia, 
and underwent additional anesthetic procedures.   
Sensitivity Studies
We redefined chronic opioid use as a total duration of opioid use (total days’ supply) that 
exceeded 90 days during 6-month follow-up period, finding that the days supplied and MME of 
the initial opioid prescription were associated with chronic opioid use according to this definition. 
An initial days supply was associated with an adjusted 1.81 fold increase in chronic use as 
compared with a supply of less than 3 days (95%CI: 1.21-2.70); while an initial MME/day of 60 
or greater was associated with an adjusted 1.37 fold increase in chronic use (95%CI: 1.00-1.87) 
as compared with an initial MME of ≤ 39.64 mg/day). These results are similar as the results 
which defined chronic use using trajectory models. 
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In another sensitivity analysis, we applied a more restricted definition of opioid naivety by only 
including patients having 12-month continuous eligibility and without any opioid dispensing or 
diagnosis of OUD during the 12 months prior to hysterectomy. In this analysis, the highest tertile 
of MME/day (exceeding 58.92 mg) for the initial opioid prescription remained predictive of 
subsequent chronic opioid use as compared with the lowest tertile of ≤ 39.64 mg/day (aOR: 
1.38; 95%CI: 1.07-1.80); while the trend for days supplied also remained consistent, albeit 
failing to reach statistical significance. (aOR: 1.38, 95%CI: 1.0-1.90 for 8+ days’ supply vs ≤3 
days’ supply)
Discussion
Hysterectomy is the most common surgical procedure among non-pregnant women. In 
our study, among the 50,127 opioid naïve women who had a hysterectomy and were dispensed 
at least one opioid prescription within 7 days after hysterectomy, 1.38% became chronic opioid 
users during the 6 months after surgery. Several demographic factors, such as age, mode of 
hysterectomy, tobacco use, alcohol use, and psychiatric use were associated with chronic 
opioid use after hysterectomy. More importantly, however, we found that characteristics of the 
initial opioid prescription, including type, dose, and duration affected the probability of chronic 
opioid use. An initial supply of 8 or more days, and an initial MME of at least 60 mg per day 
were each associated with a greater than 40% increase in the risk of subsequent chronic use of 
opioids (Table 2). Each year in the United States, there are approximately 430,000 inpatient 
hysterectomy cases.37 The findings of this study suggest that lessening the duration and amount 
of opioids in the initial opioid prescription may decrease in the risk of chronic opioid use after 
hysterectomy. 
Multiple demographic and clinical factors were associated with increased risk of chronic 
opioid use after hysterectomy, including older age, abdominal or laparoscopic/robotic 
hysterectomy, comorbidities, tobacco use, substance use disorders, certain pain conditions, and 
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use of prescription psychiatric medications use (Table 2). Our findings were similar to other 
studies that showed that these factors increase the risk of chronic opioid use after major 
cardiac, thoracic, abdominal and pelvic procedures, or specific surgeries, including cesarean 
delivery, hysterectomy, hip or knee arthroplasty, spine, or bariatric surgeries.5-17, 38, 39 These 
findings underscore the importance of considering the individual patient’s pain management 
needs,risk factors for opioid misuse at the time of opioid prescribing after hysterectomy and 
other surgical procedures, and importance of medical care, monitoring and follow-up post-
operatively . 
The literature describing the relationship between the initial opioid prescribing 
characteristics and the risk of chronic opioid use after hysterectomy among opioid naïve 
patients is limited. Prior observational studies have produced inconclusive results, which may be 
attributed to the study sample (inclusion of patients with minor surgical procedures) or small 
study sample size.11,38 Our results showed that initial opioid prescribing characteristics, including 
opioid type, daily dose, and duration of days’ supply were associated with chronic opioid use in 
the 6 months following hysterectomy among opioid naïve patients. The odds of chronic opioid 
use following initiation after hysterectomy were 31% higher among patients starting 
hydrocodone compared to patients who began therapy with oxycodone even though prior 
research has demonstrated that oxycodone is associated with risk of addiction, morbidity and 
mortality.40-42 One explanation for this finding is that for many years hydrocodone was the most 
commonly prescribed opioid medication in the United States, in part because it was a schedule 
III drug during the study period and was considered to be lesser risk than schedule II opioids 
such as oxycodone, therefore, hydrocodone may have been prescribed more liberally, 
especially to patients with a higher tendency of opioid overuse, which is a possible confounding 
by contraindication. In August 21, 2014, the U.S. Drug Enforcement Administration (DEA) 
issued stricter prescribing requirements and moved hydrocodone-containing medications from a 
Schedule III to a Schedule II controlled substance.43 Notably, the initial opioid prescribing 
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characteristics, such as longer days’ supply and higher daily morphine milligram equivalent 
dose, that were associated with post-operative chronic opioid use after hysterectomy, are also 
risk factors for opioid misuse and opioid-related mortality.44-47 By identifying modifiable risk 
factors for chronic opioid use after hysterectomy, such as pre-operative opioid prescribing, 
abdominal or laparoscopic/robotic hysterectomy, and characteristics of opioid prescribing after 
surgery, we may be able to develop strategies and interventions to decrease the likelihood of 
chronic opioid use.
There is no standard definition for chronic opioid use after surgery. We selected the 
trajectory modeling approach because of its advantages over other methods for describing 
longitudinal trajectories and identifying patients who used opioids consistently over a longer 
duration.29,30 Traditional medication adherence measures, such as the proportion of days 
covered or the number of months of continuous medication use, may not distinguish between  
consistent users in follow-up periods or between patients who discontinue medication 
completely versus those who simply have a gap in use. The trajectory models repeatedly 
assess medication use throughout the entire follow-up period and summarize long-term 
medication adherence accounting for the time-varying nature of adherence.29 We found that 
1.38% of hysterectomy patients became chronic opioid users in the 6 months after surgery. 
Using Optum data from January 01, 2011 to December 31, 2014, Swenson et al. reported 0.5% 
(122 out of 24,331) of women who had a hysterectomy had new persistent opioid use following 
hysterectomy.5 In Swenson’s study, persistent opioid use in the 6 months post-hysterectomy 
was defined as a minimum of 2 opioid prescriptions in the 6 months post-surgery (one between 
15-90 days and one at least 91-180 days) and top quartile use (amount and duration).5 The 
difference in incidence of chronic use/new persistent use between these studies is attributable 
to the use of different definitions for chronic opioid use.
          Our findings suggest that prescribing lower doses for shorter days’ supply may reduce the 
risk of subsequent chronic opioid use, and is consistent with the strategies published in 
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guidelines advocated by multiple federal and state agencies, professional societies, and 
advocacy groups. Although specific guidelines differ in exact wording and specific 
recommendations, prescribing the lowest dose for the shortest amount of time and screening for 
substance use and opioid dependence are clearly defined themes across multiple guidelines.48-
50 However, practice change solely on the basis of guidelines can be slow, and current evidence 
suggests that physicians are prescribing excess opioids to patients to control acute pain post-
surgery at hospital discharge. Studies from the surgical fields of urology, orthopedics, and 
obstetrics and gynecology have shown that physicians prescribe more than twice the amount of 
opioid medication patients actually consume post-discharge which adds up to millions of excess 
unused opioid tablets available for diversion and abuse.51-54 A recent study showed that among 
obstetricians and gynecologists, only 62% reported tailoring prescriptions to the individual 
patient and only 22% reported they performed an opioid dependence screen prior to 
prescribing.55 Improving adherence to best practices for opioid prescribing, including tailoring 
prescriptions to the individual patient’s pain management needs and risks of future opioid 
misuse and abuse, could play a major role in reducing the magnitude of the opioid epidemic. 
Limitations
First, the study subjects included in this study are commercially insured in the United 
States with 9% covered by Medicare Advantage (Table1). The demographic characteristics, 
clinical conditions, and opioid preoperative use patterns may differ from uninsured, Medicaid or 
Medicare covered populations. Thus, the study results might not be generalizable to patients 
enrolled in Medicaid or Medicare. 
Our study is subject to several limitations due to the nature of observational studies 
using claims data. Some important medical indications, such as severity of pain, which may be 
related to the hysterectomy procedure or underlying conditions leading to hysterectomy, were 
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not captured in the data. Other unmeasured confounding factors included social and economic 
factors during follow up. The low prevalence of OUDs or methadone use excluded in figure 1, 
and other substance use disorders, tobacco use, and alcohol use presented in table 1 might be 
due to poor sensitivity of ICD-9 diagnosis codes or CPT codes.  However, the impact may be 
non-differential if the unmeasured variables are similarly distributed in two comparison groups. 
Opioid analgesics were assessed using pharmacy claims, which only captured opioid 
medications legally obtained and filled at outpatient pharmacies. Patients not filling the initial 
opioid prescription post-hysterectomy may be attributed to either not using opioids for post-
surgical pain or to receiving their opioid prescription from an inpatient pharmacy.  The actual 
patterns of opioid use (actual consumption) was not measured and, based on prior studies, 
differs substantially from the amount of opioid medication prescribed. Furthermore, the result 
that hydrocodone has a higher risk of chronic use after hysterectomy compared to oxycodone 
could be due to a possible confounding by contraindication. 
The outcome assessed in this study was chronic opioid use during the first 6 months 
after hysterectomy. Although chronic opioid use within 6 months has been associated with 
opioid misuse and opioid-related death, it was not possible to differentiate whether patients 
persistently used opioids for 6 months as a treatment for pain control or because they became 
dependent upon opioids after their post-surgical pain had abated.56 Additionally, it was not 
possible to determine if the women were continuing to receive their opioid for the pain related 
to their hysterectomy or for other pain; It is possible that the reason for filling opioid 
prescriptions in the 6 months following hysterectomy was not for personal use but for 
diversion.57 Our findings that chronic opioid use post hysterectomy was significantly associated 
with initial opioid prescribing could be due to complex relationships between chronic pain post-
surgery, acute pain post-surgery, and chronic pain pre-surgery.
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Conclusions
In this study, approximately 3 in 200 opioid naïve women appear to become chronic 
opioid users after hysterectomy. Besides commonly recognized demographic and clinical risk 
factors, chronic opioid use after hysterectomy was associated with initial opioid prescribing 
characteristics, such as longer days’ supply and higher daily opioid dose. Although prescription 
opioid medications provide effective analgesia after surgery, they must be used with caution 
given the potential risk for subsequent chronic opioid use that is associated with opioid misuse 
and overdose-related mortality. Our findings support the need to manage post-surgical pain with 
the least amount of opioid medication possible to effectively control a patient’s symptoms, and 
close clinical post-op follow-up for those patients who prescribed opioids.  
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Figure 1. Flow Chart of the Study Population.
N=157,934 patients had 
hysterectomy between 07/01/2010 
and 03/31/2015. 
N= 121,052 cancer free patients
Excluded 18,202 patients with no 
opioid prescription fill within 7 days 
of hysterectomy
N=135,748 patients had 
continuous enrollment
Excluded 22,186 patients without 
continuous enrollment for 6 
months prior to hysterectomy
Excluded 14,696 patients who had 
cancer diagnosis or radical 
hysterectomy
Excluded 48,778 patients used 
prescription opioids and 232 were 
diagnosed OUDs within 6 months 
prior to hysterectomy. 
N=54,045
Opioid naïve patients who 
received opioids within 7 days of 
hysterectomy
Final study cohort 
N=50,127
Excluded 3,918 patients who were 
missing important demographic 
data
Abdominal 
Hysterectomy
N=12,986 (26%)
Laparoscopically 
assisted hysterectomy 
N= 29,640 (59%)
Vaginal 
hysterectomy 
N= 7,502 (15%)
N=72,247
Opioid naïve patients
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Figure 2. Trajectories of filling opioid prescriptions in 6 months post hysterectomy. The solid or 
dashed lines represent the distinct estimated opioid prescription filling trajectories. The dot 
symbols represent the mean estimated proportion in each trajectory group dispensed an opioid 
prescription at each month. These indicate the mean estimated probability of filling an opioid 
prescription for patients in each group at each time point. Overall counts and percentages of 
patients in each group are presented in the underneath table. Patients in trajectory 4 were 
classified as opioid chronic users. Patients in trajectories 1, 2, 3 were classified as opioid non-
chronic users. The x-axis indicates each 30-day interval during the 6-month follow-up period, 
while the y-axis indicates the estimated proportion of patients filled a prescription opioid within 
each 30-day interval.
Trajectories Trajectory 1 Trajectory 2 Trajectory 3 Trajectory 4
N (%) 39,677 (79.15%) 3,304 (6.59%) 6,453 (12.87%) 693 (1.38%)
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Table 1. Comparison of baseline patient characteristics among opioid-naïve patients who 
received prescription opioids within 7 days after hysterectomy, N=50,127
Patient characteristics Non-chronic 
Users†
(N=48,434)
Chronic Opioid Users‡
(N= 693)
P-value
Charlson Comorbidity Index, mean (95% CI) 1.60 (1.57, 1.64) 1.74 (1.45, 2.02) 0.3479
Length of stay in days, mean (95% CI) 2.32 (2.30, 2.35) 3.79 (3.39, 4.19) <0.0001
Age, years, mean (95% CI) 48.1 (48.0, 48.2) 49.8 (48.9,50.7) 0.0004
Age at hysterectomy, years
       <40
       40-49
       50+
9,100 (18.41) 
22,538 (45.59) 
17,796 (36.00)
126 (18.18)
255 (36.80) 
312 (45.02)
<.0001
Substance use and abuse, N (%)
      Tobacco
       Alcohol
       Other substance use disorders§
2,637 (5.33) 
177 (0.36) 
55 (0.11)
60 (8.66) 
9 (1.30) 
4 (0.58)
0.0001
 <.0001
0.0004
Psychiatric medications, N (%)
       Benzodiazepines
       Antidepressants
       Stimulants
4,201 (8.50) 
9,984 (20.20) 
767 (1.55)
125 (18.04) 
233 (33.62)
25 (3.61)
<.0001
< .0001
< .0001
Pain conditions, N (%)
       Fibromyalgia
       Headache syndromes
       Back pain
1,530 (3.10) 
4,019 (8.13)
4,659 (9.42)
30 (4.33) 
82 (11.83) 
110 (15.87)
0.0632
0 .0004
< .0001
Type of hysterectomy, N (%)
       Abdominal hysterectomy
       Vaginal hysterectomy     
        Laparoscopic/Robotic
12,757 (25.81) 
7,428 (15.03 
29,249 (59.17)
228 (32.90) 
74 (10.68) 
391 (56.42)
<.0001
Surgery setting, N (%)
       Inpatient
       Outpatient
19,805 (40.06) 
29,629 (59.94)
352 (50.79) 
341 (49.21)
<.0001
US census region, N (%)
       Midwest
       Northeast
       South
       West
13,705 (27.72) 
5,075 (10.27) 
23,642 (47.83) 
7,012 (14.18)
186 (26.84) 
66 (9.52) 
332 (47.91) 
109 (15.73)
0.6351
Insurance type, N (%)
       Commercial
       Medicare
45,107 (91.25) 
4,327 (8.75)
586 (84.56) 
107 (15.44)
< .0001
Type of health plan, N (%)
       Exclusive provider organization
       Health maintenance organization
       Point of service
       Others¶
5,990 (12.12) 
4,913 (9.94)
34,004 (68.79) 
4,527 (9.16)
70 (10.10) 
89 (12.84) 
449 (64.79) 
85 (12.27)
0.0008
Year of hysterectomy
      2010-2013  
      2014-2015
21,949 (44.40) 
27,485 (55.60)
287 (41.41) 
406 (58.59)
0.1161
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Initial Opioid Prescription Characteristics
Days’ supply, days 4.85 (4.82, 4.87) 5.12 (4.89, 5.34) 0.0205
Average daily MME, mg/day 54.7 (54.3, 55.0) 58.4 (54.6, 62.2) 0.0571
Type of Opioid, N(%)
       Hydrocodone
       Oxycodone
       Other
17,555 (35.51) 
27,434 (55.50) 
4,445 (8.99)
266 (38.38) 
354 (51.08) 
73 (10.53)
0.0553
Tertile MME, mg/day
        <=40
        40.5-58.9
        60.0+ 
16,154 (32.68) 
16,718 (33.82) 
16,562 (33.50)
219 (31.60) 
221 (31.89) 
253 (36.51)
0.2425
Days’ supply, days
        1-3
        4-7
        8+
15,667 (31.69) 
29,098 (58.86) 
4,669 (9.44)
193 (27.85) 
423 (61.04) 
77 (11.11)
0.0566
Abbreviation: MME=Morphine Milligram Equivalent
†Non-chronic users refer to patients in trajectory 1, 2, and 3 in Figure 2.  
‡Chronic Opioid users refer to patients in trajectory 4 in Figure 2.
§Other substance use includes cocaine, marijuana, anxiolytic, stimulant, hallucinogenic drugs, or abuse 
of unspecified drugs/medications. 
¶Others include Indemnity and Preferred provider organization.
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Table 2. Baseline and initial opioid prescription characteristics that predict chronic opioid use 
following hysterectomy among opioid naive patients, 2010-2015; N=50, 127
Characteristics Unadjusted OR (95% CI) Adjusted OR† (95% CI)
Age group, years
       40-49
       < 40
       ≥ 50
Ref.
1.22 (0.99, 1.52)
1.55 (1.31, 1.83)
Ref.
1.20 (0.97, 1.49)
1.37 (1.14 1.65)
Insurance type
       Commercial
       Medicare
Ref.
1.90 (1.55, 2.35)
Ref.
1.98 (1.37, 2.87
Type of health plan, N (%)
       Exclusive provider organization
       Health maintenance organization
       Point of service
       Others‡
Ref.
1.55 (1.13, 2.13)
1.13 (0.88, 1.46)
1.61 (1.17, 2.21)
Ref.
1.19 (0.84, 1.68)
1.10 (0.85, 1.42)
0.75 (0.48, 1.18)
Type of hysterectomy
       Vaginal hysterectomy 
       Laparoscopic/Robotic       
       Abdominal hysterectomy     
Ref.
1.79 (1.38, 2.34)
1.34 (1.05, 1.72)
Ref.
1.52 (1.16, 2.00)
1.40 (1.09, 1.80)
Year (2010-2013 vs 2014-2015) 1.13 (0.97, 1.32) 1.24 (1.06, 1.46)
Length of stay (days) 1.14 (1.11, 1.16) 1.12 (1.10, 1.15)
Charlson comorbidity index 1.18 (1.06, 1.31) 1.16 (1.04, 1.30)
Pain conditions
       Headache (Yes vs. No)      
       Back pain (Yes vs. No)
1.52 (1.20, 1.91)
1.81 (1.48, 2.23)
1.33 (1.04, 1.69)
1.57 (1.27, 1.94)
Substance use 
       Alcohol
       Tobacco
3.66 (1.87, 7.18)
1.68 (1.29, 2.20)
1.84 (0.91, 3.74)
1.47 (1.12, 1.93)
Psychiatric medications
       Antidepressants
       Benzodiazepines
       Psychostimulants
2.00 (1.71, 2.35)
2.37 (1.95, 2.88)
2.38 (1.58, 3.56)
1.71 (1.45, 2.03)
1.89 (1.54, 2.33)
1.84 (1.21, 2.80)
Initial Opioid Prescription Characteristics
Type of opioid
        Oxycodone
        Hydrocodone
        Other
Ref.
1.17 (1.00, 1.38)
1.27 (0.99, 1.64)
Ref.
1.31 (1.10, 1.57)
1.26 (0.96, 1.64)
Days’ supply, days
        ≤ 3
        4-7
        ≥ 8
Ref.
1.18 (0.99, 1.40)
1.34 (1.03, 1.75)
Ref.
1.28 (1.06, 1.54)
1.41 (1.05, 1.89)
Tertile MME, mg/day
        < 40
        40 -58.9
        ≥ 60.0
Ref.
0.98 (0.81, 1.18)
1.13 (0.94, 1.35)
Ref.
1.14 (0.93, 1.40)
1.43 (1.14, 1.79)
Abbreviation: MME=Morphine Milligram Equivalent
Adjusted model: c-statistic = 0.70; Hosmer-Lemeshow Goodness-of-fit Test: X2 =19.30, df=8, p=0.0133
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†Adjusted for baseline patient demographic and clinical characteristics listed in this table.
‡Others include Indemnity and Preferred provider organization.
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Table 3. Distribution of possible indications for chronic opioid use during the 6-month follow-up 
period after hysterectomy: shown as N (%).
Possible indications All patients in 
cohort
(N = 50,127)
Non-chronic 
Users
(N = 49,434)
Chronic Opioid 
Users
(N = 693)
P-value
Chronic pancreatitis
Headache syndromes
Back pain
Fibromyalgia
Additional anesthetic 
procedures†
0
1
2
≥ 3
70 (0.14)
3,284 (6.55)
4,477 (8.93)
1,470 (2.93)
46,132 (92.03) 
3,310 (6.60) 
525 (1.05) 
160 (0.32)
63 (0.13)
3,196 (6.47)
4,287 (8.67) 
1,407 (2.85)
45,768 (92.58) 
3,099 (6.27) 
459 (0.93) 
108 (0.22)
7 (1.01)
88 (12.70)
190 (27.42)
63 (9.09)
364 (52.53) 
211 (30.45)
  66 (9.52)
52 (7.50)
<.0001
< .0001
< .0001
< .0001
< .0001
†Number of additional procedures requiring anesthesia. 
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eTable 1. Operational definitions of essential baseline covariates 
Patient characteristics Operational definitions
Age Age in years as of the date of the hysterectomy (index date). 
Age was categorized as <40, 40–49, and ≥50 years.
Charlson comorbidity index The Charlson Comorbidity Index was to categorize 
comorbidities based on the presence of ICD-9 and ICD-10 
diagnosis codes. A weighted sum provided in a single 
comorbidity score for a patient. We used a Quan’s enhanced 
Charlson and Elixhauser comorbidity index.
Length of stay Length of stay refers to the duration of hospitalization and 
clinical stay for the index hysterectomy procedure.
Year The calendar year of the index date was divided into early 
(2010 to 2012) and late (2013 to 2015) and included in the 
model as a dichotomous variable.
Type of hysterectomy Identified using ICD9 procedure codes and CPT codes
Opioid use disorder ICD9 diagnosis codes for opioid use disorder and 
buprenorphine and methadone used for medication-assisted 
treatment. 
Non-rule-out cancer diagnosis Defined as ≥ 2 separate cancer diagnoses occurred ≥ 42 days 
apart or 1 cancer diagnosis with ≥ 1 procedures, including 
chemotherapy, radiation, or cancer-related surgery.25 
Chronic opioid use To identify chronic opioid use after hysterectomy group-based 
trajectory models were used to group together patients with 
similar patterns of medication filling during follow-up. The 
group with the highest filling probability was classified as 
chronic users.
Psychiatric medications Psychotropic medication use during baseline identified using 
the American Hospital Formulary System (AHFS) Therapeutic 
codes and national drug codes 
Pain conditions (fibromyalgia, 
headache syndromes, back pain)
Identified using ICD-9 diagnosis codes
Substance use and abuse (tobacco, 
alcohol, marijuana, cocaine, etc.)
Identified using ICD-9 diagnosis codes
US census region US census region refers to the region where patient had the 
hysterectomy procedure as defined by the US Census Bureau
Insurance type All patients in the database are insured. There were two types 
of insurance: commercial or Medicare.
Characteristics of initial opioid prescription
Type of opioid The first opioid prescriptions filled were classified as 
Oxycodone, Hydrocodone, or other (Codeine, Fentanyl, 
Hydromorphone, Meperidine, Morphine, Pentazocine, 
Tapentadol, and Tramadol).
Number of days’ supply Number of days’ supply for the first opioid prescription after 
hysterectomy was divided into 3 categories (1-3 days, 4-7 days, 
and 8 or more days).
MME tertiles The morphine milligram equivalent daily dose for the initial 
opioid prescription was determined, and the daily dose was 
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divided into tertiles for the analysis (corresponding to 
thresholds of ≤40 mg, 40.50 mg to 57.86 mg and ≥58.33 mg of 
oral morphine equivalent).
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eTable 2. Comparison of baseline patient characteristics among four trajectory-based 
model groups, N=50,127
Patient characteristics TBM Group 1
(N=39,677)
TBM Group 2
(N= 3304)
TBM Group 3
(N= 6453)
TBM Group 4
(N=693)
LOS in days, mean (95% 
CI)
2.23 (2.20, 
2.25)
2.46 (2.34, 
2.58)
2.77 (2.68, 
2.86)
3.79 (3.39, 
4.19)
CCI, mean (95% CI) 1.59 (1.54, 
1.63)
1.71 (1.57, 
1.85)
1.63 (1.52, 
1.75)
1.74 (1.45, 
2.02)
Age (years), mean (95% CI) 48.27 (48.17, 
48.38)
48.30 (47.92, 
48.67)
47.17 (46.92, 
47.42)
49.77 (48.87, 
50.67)
Age at hysterectomy 
(years), N (%)
       < 40
       40-49
       ≥ 50
7086 (17.86)
18119 (45.67)
14472 (36.47)
666 (20.16)
1411 (42.71)
1227 (37.14)
1348 (20.89)
3008 (46.61)
2097 (32.50)
126 (18.18)
255 (36.80)
312 (45.02)
Substance use and abuse, N 
(%)
       Tobacco use
       Alcohol abuse
       Other substance abuse†
1907 (4.81)
117 (0.29)
41 (0.10)
230 (6.96)
12 (0.36)
3 (0.09)
500 (7.75)
48 (0.74)
11 (0.17)
60 (8.66)
9 (1.30)
4 (0.58)
Psychiatric medications
       Benzodiazepines
       Antidepressants
       Psychostimulants
3071 (7.74)
7485 (18.86)
556 (1.40)
355 (10.74)
878 (26.57)
86 (2.60)
775 (12.01)
1621 (25.12)
125 (1.94)
125 (18.04)
233 (33.62)
25 (3.61)
Pain conditions, N (%)
       Fibromyalgia
       Headache syndromes
       Back pain
1144 (2.88)
3012 (7.59)
3624 (9.13)
155 (4.69)
356 (10.77)
363  (10.99)
231 (3.58)
651 (10.09)
672 (10.41)
30 (4.33)
82 (11.83)
110 (15.87)
Type of hysterectomy, N 
(%)
       Vaginal hysterectomy 
       Laparoscopic/Robotic 
       Abdominal 
hysterectomy 
9779 (24.65)
6113 (15.41)
23785 (59.95)
773 (23.40)
499 (15.10)
2032 (61.50)
2205 (34.17)
816 (12.65)
3432 (53.18)
228 (32.90)
74 (10.68)
391 (56.42)
US census region, N (%)
       Midwest
       Northeast
       South
       West
11101 (27.98)
4232 (10.67)
18700 (47.13)
5644 (14.22)
900 (27.24)
313 99.47)
1654 (50.06)
437 (13.23)
1704 (26.41)
530 (8.21)
3288 (50.95)
931 (14.43)
186 (26.84)
66 (9.52)
332 (47.91)
109 (15.73)
Insurance type, N (%)
       Commercial
       Medicare
36225 (91.30)
3452 (8.70)
2964 (89.71)
340  (10.29)
5918 (91.71)
535 (8.29)
586 (84.56)
107 (15.44)
Type of health plan, N (%)
       Exclusive provider 
organization
       Health maintenance 
organization
       Others‡
       Point of service
4779 (12.04)
3981 (10.03)
3646 (9.19)
27271 (68.73)
408 (12.35)
320  (9.69)
333 (10.08)
2243 (67.89)
1,061 (12.54)
867 (10.24)
647 (7.65)
5,888 (69.57)
70 (10.10)
89 (12.84)
85 (12.27)
449 (64.79)
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Abbreviations: TBM=Trajectory based model; CCI= Charlson Comorbidity Index; LOS=Length of stay; 
MME=Morphine milligram equivalent; 
†Other substance use includes marijuana, cocaine, anxiolytic, stimulant, hallucinogenic drugs, or abuse 
of unspecified drugs/medications.
‡Others include Preferred Provider Organization and Indemnity.
Initial Opioid Prescription Characteristics
Days’ supply (days), mean 
(95% CI)
4.83 (4.81, 
4.86)
4.86 (4.76, 
4.95)
4.95 (4.88, 
5.02)
5.12 (4.89, 
5.34)
Avg. MME, mg/day (95% 
CI)
54.37 (53.99, 
54.75)
55.93 (54.33, 
57.54)
56.04 (54.96, 
57.11)
58.39 (54.60, 
62.18)
Type of Opioid, N (%)
       Hydrocodone
       Oxycodone
       Other
13697 (34.52)
22431 (56.53)
3549 (8.94)
1241 (37.56)
1766 (53.45)
297 (8.99)
2617 (40.55)
3237 (50.16)
599 (9.28)
266 (38.38)
354 (51.08)
73 (10.53)
Days’ supply (days), N (%)
       1-3
       4-7
       ≥ 8
12703 (32.02)
23273 (58.66)
3701 (9.33)
1048 (31.72)
1951 (59.05)
305 (9.23)
1916 (29.69)
3874 (60.03)
663 (10.27)
193 (27.85)
423 (61.04)
77 (11.11)
Tertile MME (mg/day), N 
(%)
       < 40
       40 – 58.93
       ≥ 60
13034 (32.85)
13412 (33.80)
13231 (33.35)
1079 (32.66)
1102 (33.35)
1123 (33.99)
2041 (31.63)
2204 (34.15)
2208 (34.22)
219 (31.60)
221 (31.89)
253 (36.51)
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Chronic Opioid Use in Women following Hysterectomy: Patterns and Predictors
Xuerong Wen,1 PhD, MPH, Stephen Kogut,1 PhD, Hilary Aroke,1 MD, PhD, MPH, Lynn Taylor1, 
MD, Kristen A. Matteson,2 MD, MPH,
1. Health Outcomes Research, Department of Pharmacy Practice, College of Pharmacy, 
University of Rhode Island. 
2. Obstetrics and Gynecology, Women & Infants Hospital and the Warren Alpert Medical 
School, Brown University.
Page 35 of 78
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Abstract
Background Most women are prescribed an opioid at hospital discharge after hysterectomy. 
The objective of this study was to determine the association between initial opioid prescribing 
characteristics and chronic opioid use after hysterectomy. 
Methods: This study included women enrolled in a commercial health plan who had a 
hysterectomy between July 01, 2010 and March 31, 2015. We used trajectory models to define 
chronic opioid use as patients with the highest probability of having an opioid prescription filled 
during the 6 months post-surgery. We used multivariable logistic regression to examine the 
association between initial opioid dispensing (amount prescribed and duration of treatment) and 
chronic opioid use after adjusting for potential confounders. 
Results: A total of 434 693 of 49,84450,127 (0.91.38%) opioid naïve women met the criteria for 
chronic opioid use following hysterectomy. The baseline variables and initial opioid prescription 
characteristics predicted the pattern of long-term opioid use with moderate discrimination (c 
statistic = 0.730.70). Significant predictors of chronic opioid use included initial opioid daily dose 
(≥60 MME vs < 40 MME, aOR: 1.701.43, 95%CI: 1.281.14-2.261.79), and days’ supply 4-7 days 
vs 1-3 days, aOR: 1.411.28, 95%CI: 1.111.06-1.791.54; ≥8 days vs 1-3 days, aOR: 2.041.41, 
95%CI: 1.431.05-2.901.89). Other significant baseline predictors included older age, abdominal 
or laparoscopic/robotic hysterectomyhysterectomy type, tobacco use, co-morbiditiespsychiatric 
medication use, back pain, and fibromyalgiaheadache.
Conclusion: Initial opioid prescribing characteristics are associated with risk of chronic opioid 
use after hysterectomy. Prescribing lower daily doses and shorter days’ supply of opioids to 
women after hysterectomy may result in lower risk of chronic opioid use.  
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Introduction
The rapid increase in the incidence of opioid-related overdoses and deaths has become 
a major public health issue crisis in the United States. Overdose and death from prescription 
opioid overdose increased 400% in women between 1999 and 2013.1-3 For many women, their 
first exposure to prescription opioids often occurs during the post-operative period, which makes 
this a potential target for strategies to reduce the risk of chronic opioid use.4-6 Several 
observational studies suggest that surgery is a risk factor for chronic opioid use.5-18 Two studies 
have examined the relationship between the initial opioid prescribing characteristics and chronic 
opioid use in the postoperative setting and arrived at contradictory conclusions.6,12 One study 
reported that initial exposure to prescription opioids after minor surgery increases the risk of 
chronic opioid use by 44%,12 while the other suggested that the initial opioid prescribing 
characteristics, including type of opioid dispensed, days’ supply, or daily dose (in morphine 
milligram equivalents), were not associated with chronic opioid use after cesarean delivery.6 
Hysterectomy, the most commonly performed non-obstetric surgery among women in 
the United States,19-21 poses a potential risk for chronic opioid use because an estimated 82% of 
hysterectomy patients receive an opioid prescription at hospital dischargeafter the hysterectomy 
surgery.20,22 However, the relationship between the initial opioid prescribing characteristics and 
chronic opioid use after hysterectomy remains largely unknown. The objective of this study was 
to identify baseline risk factors for chronic opioid use after hysterectomy and examine the 
association between initial opioid prescribing characteristics after hysterectomy and subsequent 
chronic use of opioids among opioid naïve women.
Methods
Data Sources: Study data were derived from the national OptumInsight Clinformatics Data 
MartTM (OptumInsight, Eden Prairie, MN). The Optum Clinformatics Data Mart is an 
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administrative health claims database from a large national insurer which includes 
approximately 35 million beneficiaries. The dataset contains transactional reimbursement data 
for health care utilization including outpatient pharmacy dispensing, and inpatient and outpatient 
medical claims.23 The administrative enrollment file has eligibility information, the outpatient 
pharmacy file has the national drug code (NDC) for each drug dispensed, and the medical files 
have the Current Procedural Terminology (CPT) code for medical procedure, and International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for medical 
procedure and diagnosis. Patients included in the database had both medical and prescription 
coverage. The data was used under license agreement between the University of Rhode Island 
and OptumInsight Inc. 
Study Population: This study included women (≥ 18 years) who had a hysterectomy between 
July 01, 2010 and March 30, 2015. Women were required to have at least 6 months of 
continuous enrollment prior to hysterectomy. To identify an opioid-naïve study cohort, we 
excluded women with a diagnosis of opioid use disorders or any opioids filled 6 months before 
the date of the hysterectomy (index date) (eTable 1). The hysterectomy procedures were 
identified using ICD-9-CM procedure and CPT codes from both the inpatient and outpatient 
claims (eTable 1).21,24 We excluded patients who had a radical hysterectomy and patients for 
whom we could not rule-out a cancer diagnosis which was defined as ≥ 2 separate medical 
claims with a cancer diagnosis occurred ≥42 days apart or receipt of chemotherapy, radiation, 
or other cancer-related surgery (eTable 1).25 Women who filled at least one opioid prescription 
at a retail pharmacy within 7 days of discharge were considered exposed to prescription opioids 
and included in the final study cohort. The 7-day window was based on the assumption that an 
opioid prescription filled by an opioid naïve individual during this period was likely used to treat 
acute pain after hysterectomy. This study was approved by the University of Rhode Island 
Institutional Review Board (IRB#957873-2). 
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Exposure to opioids: Opioid prescriptions were identified using national drug codes (NDC) 
from the outpatient pharmacy claims. Opioid prescriptions were classified as hydrocodone, 
oxycodone and others (including codeine, fentanyl, hydromorphone, meperidine, morphine, 
pentazocine, tapentadol, and tramadol). Duration of the initial prescription was categorized as 1-
3, 4-7, ≥ 8 days. We calculated the morphine milligram equivalent (MME) for the initial opioid 
prescription using the Center for Disease Control (CDC) conversion Tables (2016 version). The 
average daily MME dose was categorized into tertiles (≤40mg/day, 40.50-58.9mg/day, and 
≥60mg/day). 
Outcome Assessment: We used trajectory models to generate our dichotomous primary study 
outcome as (chronic opioid use after hysterectomy present or absent).11 The trajectory models 
allow the use of observed longitudinal data to determine distinct opioid prescription filling 
patterns in the study population during the six months period after hysterectomy. This approach 
classifies patients into groups with similar opioid prescription filling patterns during follow-up 
without relying on a priori and often subjective prespecified cutoff value for the definition of 
chronic opioid use.26,27 In order to classify the trajectory groups for opioid use during the defined 
follow-up window (6 months after hysterectomy), we first generated 6 dichotomous variables to 
indicate if a study participant filled a prescription of an opioid analgesic during each of 6 
consecutive 30-day follow-up periods, e.g., month 1 is from 7 to 37 days, month 2 is from 37 to 
67 days, and month 6 is from 157 to 187 days.11 We then modeled these 6 binary indicators of 
opioid use in each 30-day follow-up period as a longitudinal response in a logistic group-based 
trajectory.28,29 Using the trajectory model, we estimated the probability of membership of patients 
in each group, and the probability of filling an opioid prescription over time as a smooth function 
of time. The model was fitted using 2 to 6 5 opioid exposure groups and the number of groups 
was chosen based on the value of the Bayesian Information Criterion.30 In each group, a third-
order polynomial (including linear, squared, and cubic terms) of time were used to model the 
probability of filling a prescription for opioids. Patients were assigned to the trajectory group in 
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which they had the highest probability of membership. Based on the model results, the 
trajectory group with the highest probability of filling any opioid prescription beyond the initial 
prescription was defined as “chronic opioid users”. All other trajectory groupings were classified 
as non-chronic opioid users. The percentage of patients who filled an opioid prescription was 
reported in each trajectory for every consecutive 30-day follow-up period. 
Potential Predictors of Chronic Opioid Use: We collected data on potential confounding 
variables that may be related to both initial opioid prescribing characteristics and chronic opioid 
use after hysterectomy.6-11,31 Previous studies demonstrated that age, certain pain conditions, 
and psychiatric disorders are associated with both postsurgical chronic pain and chronic 
prescription opioid use.6,21,31-36 Covariates assessed  in our analyses included age at 
hysterectomy, Charlson comorbidity index, hospital length of stay, smoking status, use of 
alcohol and illicit substances, psychiatric medication use, pre-operative pain conditions, types of 
hysterectomy procedure performed, US census region, type of insurance (Medicare or private 
insurance) and health plan (exclusive provider organization, health maintenance organization, 
point of service, and others including indemnity and preferred provider organization), year of 
surgery, and initial opioid prescribing characteristics (medication type, average daily dose, and 
number of days’ supplied).
Statistical Analysis: Categorical variables were examined and compared using Chi-squared or 
Fisher exact tests. Continuous variables were compared using the student t test. Statistical tests 
and modeling were conducted to identify risk factors for chronic opioid use among women after 
hysterectomy. A multivariable logistic regression model was used to estimate the association 
between baseline demographic and clinical variables, initial opioid prescribing characteristics, 
and chronic opioid use after hysterectomy among opioid-naive patients who filled at least one 
opioid prescription within 7 days after hysterectomy. 
Sensitivity studies were conducted using multivariate logistic regression models to 
examine if the significant association between initial prescribing pattern and subsequent chronic 
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opioid use were upheld with a different definition of chronic opioid use post hysterectomy or a 
more restricted definition for opioid naivety after adjusting for other covariates. 
A probability of type 1 error (alpha) = 0.05 was set as the threshold of statistical 
significance. The trajectory models were conducted using “Proc Traj”. All statistical analyses 
were performed using Statistical Analysis Software (SAS), version 9.4 (SAS Institute Inc, 
Cary, NC). 
Results
Study cohort: A total of 157,934 women underwent hysterectomy between 07/01/2010 and 
03/31/2015. Of these patients, 22,186 (14%) patients did not meet the continuous enrollment 
criteria, 14,696 (9%) had suspected cancer diagnoses or radical hysterectomy, 23,70718,202 
(12%) didn’t fill an opioid prescription within 7 days of surgery, 3,8103,918 (2%) were missing 
important demographic data, 43,30348,778 (31%) used opioids in the 6 months prior to surgery 
and 232 (0.1%) were diagnosed with OUDs within 6 months prior to hysterectomy, leaving 
49,84450,127 (32%) patients for the analysis. In the final study cohort, only 3 patients lost 
eligibility and were censored during the 6-month follow-up period. A total of 12,966 985 (26%) 
patients had an abdominal hysterectomy; 29,409 640 (59%) patients had a laparoscopic or 
robotic assisted laparoscopic hysterectomy; and 7,469 502 (15%) patients had a vaginal 
hysterectomy (Figure 1). 
The trajectory model identified 4 distinct trajectories of prescription opioid use after 
hysterectomy, with total 39,677 (79.15%) patients in trajectory 1, 3,304 (6.59%) in trajectory 2, 
6,453 (12.87%) in trajectory 3, and 693 (1.38%) in trajectory 4. (Figure 2). Among the patients in 
trajectory 4 (n=434693, 0.871.38%), 7057%, 6055%, 6857%, 7655%, 7248%, and 5341% filled 
an opioid prescription at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months 
following an initial prescription in the 7 days post-hysterectomy, respectively.  Patients in 
trajectory 4 were classified as chronic opioid users. No patient in trajectory 1 (n=39,677, 
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79.15%) filled any opioid prescription (0%) from month 1 to 6. Among patients in trajectory 1 2 
(n=2,8083,304, 5.66.59%), 500.3% filled a prescription at month 1, which increased to 2.6% at 
month 2, 8% at month 3, and then followed by 10% with opioid fills for the subsequent 3 
monthsgradually decreased in each subsequent month to 0% with an opioid prescription fill at 
month 5. Thirty-two five percent of patients in trajectory 2 3 (n=2,5436,543, 5.112.87%) filled an 
opioid prescription at month 1, which decreased to 58% at month 2, and then gradually 
increased decreased to from 4% at month 3, and  to 293% at months 4, 5, and 6. Among 
patients seen in trajectory 3 (n=44,059, 88.4%), 24% filled an opioid prescription at month 1 
followed by 0% with opioid fills for the subsequent 5 months. A description of the demographic 
and clinical characteristics of the patients assigned to each of these 4 trajectories is included in 
eTable2. 
Characteristics of patients and initial prescriptions: Among the total 49,84450,127 opioid 
naïve patients who filled at least one opioid prescription within 7 days after hysterectomy, 434 
693 (0.871.38%) patients were categorized as chronic opioid users and 
49,41048,434(99.1398.62%) were categorized as non-chronic users. Baseline characteristics 
among chronic opioid users after hysterectomy were significantly different from non-chronic 
opioid users (Table 1). Compared to the women without chronic opioid use, women with chronic 
opioid use were older and more likely to have a higher Charlson comorbidity index, a history of 
tobacco use, and a history of alcohol use. Chronic opioid users also were also more likely to be 
taking psychiatric medications, including benzodiazepines, antidepressants, and stimulants. 
Back pain and headache syndromes fibromyalgia were more prevalent in the chronic opioid use 
group. Compared to women with commercial insurance, women with Medicare insurance had 
higher rates of chronic opioid use. About 1.5 percent of Medicare patients who were chronic 
opioid users after hysterectomy were younger than 65. 
In unadjusted analyses, the average daily MME/day and the type of the initial opioid 
prescription were similar between women categorized as having chronic use and not having 
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chronic opioid use. The days’ supplied of the initial opioid was marginally greater among chronic 
users than for non-chronic users (5.12 versus 4.85 days, respectively, p = 0.0205) (Table 1). 
Overall, oxycodone was more frequently prescribed hydrocodone or other opioids. 
Predictors of chronic opioid use among all patients in the study: The results of 
multivariable logistic regression analyses are shown in Table 2. A number of factors were 
significantly associated with chronic opioid use after hysterectomy including older age, 
geographic region, abdominal or laparoscopic/robotic hysterectomymode of hysterectomy, 
Charlson comorbidity index, tobacco use, alcohol use, and prescribed psychotropic 
medicationsother substance use, benzodiazepines use, antidepressants use, antipsychotics 
use, stimulants use. Pain conditions, including headache syndromes fibromyalgia and back pain 
at baseline, were also identified as significant risk factors for chronic opioid use after 
hysterectomy. Health plan type, census region, surgical setting, fibromyalgia, and other 
substance use disorders were not included in the final multivariable analyses due to lack of 
significance.   
The characteristics of the initial opioid prescription, including type of opioid dispensed, 
days’ supply, and daily dose in MME, were fitted in the model. Days’ supply and daily dose in 
MME were divided into their tertiles. Among initial opioid prescribing characteristics, significant 
predictors of chronic opioid use were initial prescription of hydrocodone (compared to 
oxycodone, aOR: 1.3331, 95%CI: 1.1110-1.5957), days’ supply (4-7 days vs ≤3 days, aOR: 
1.3528, 95%CI: 1.1106-1.7954; ≥8 days vs ≤ 3 days, aOR: 2.041.41, 95%CI: 1.4305-2.901.89), 
and daily dose in MME (≥60 mg/day vs ≤40 mg/day, aOR: 1.7043, 95%CI: 1.2814-2.261.79), 
The C-statistic for the fitted full model was 0.7370, indicating moderate predictability (Table 2)
The frequencies of post-surgery complications and other conditions associated with pain 
during the 6-month follow-up were examined in the study cohort (Table 3). Compared with non-
chronic opioid users, women who developed chronic opioid use after hysterectomy were more 
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frequently diagnosed with chronic pancreatitis, headache syndrome, back pain, fibromyalgia, 
and underwent additional anesthetic procedures.   
Sensitivity Studies
We redefined chronic opioid use as a total duration of opioid use (total days’ 
supply) that exceeded 90 days during 6-month follow-up period, finding that the days supplied 
and MME of the initial opioid prescription were associated with chronic opioid use according to 
this definition. An initial days supply was associated with an adjusted 1.81 fold increase in 
chronic use as compared with a supply of less than 3 days (95%CI: 1.21-2.70); while an initial 
MME/day of 60 or greater was associated with an adjusted 1.37 fold increase in chronic use 
(95%CI: 1.00-1.87) as compared with an initial MME of ≤ 39.64 mg/day). These results are 
similar as the results which defined chronic use using trajectory models. 
In another sensitivity analysis, we applied a more restricted definition of opioid naivety by only 
including patients having 12-month continuous eligibility and without any opioid dispensing or 
diagnosis of OUD during the 12 months prior to hysterectomy. In this analysis, the highest tertile 
of MME/day (exceeding 58.92 mg) for the initial opioid prescription remained predictive of 
subsequent chronic opioid use as compared with the lowest tertile of ≤ 39.64 mg/day (aOR: 
1.38; 95%CI: 1.07-1.80); while the trend for days supplied also remained consistent, albeit 
failing to reach statistical significance. (aOR: 1.38, 95%CI: 1.0-1.90 for 8+ days’ supply vs ≤3 
days’ supply)
Discussion
Hysterectomy is the most common surgical procedure among non-pregnant women. In 
our study, among the 49,84450,127 opioid naïve women who had a hysterectomy and were 
dispensed at least one opioid prescription within 7 days after hysterectomy, 0.871.38% became 
chronic opioid users during the within 6 months after surgery. Several demographic factors, 
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such as age, mode of hysterectomy, tobacco use, alcohol use, and psychiatric use were 
associated with chronic opioid use after hysterectomy. More importantly, however, we found 
that characteristics of the initial opioid prescription, including type, dose, and duration affected 
the probability of chronic opioid use. An initial supply of 8 or more days, and an initial MME of at 
least 60 mg per day were each associated with a greater than 40% increase in the risk of 
subsequent chronic use of opioids (Table 2). Each year in the United States, there are 
approximately 430,000 inpatient hysterectomy cases.37 The findings of this study suggest that 
lessening the intensityduration and amount of opioids in the initial focusing on these easily 
modifiable opioid prescription characteristics may lead to decrease in the risk incidence of 
chronic opioid use after hysterectomy. this prevalent surgical procedure.The findings of this 
study suggest that we could focus on these easily modifiable opioid prescription characteristics 
to decrease the incidence of chronic opioid use after this prevalent surgical procedure.
Multiple demographic and clinical factors were associated with increased risk of chronic 
opioid use after hysterectomy, including older age, abdominal or laparoscopic/robotic 
hysterectomymode of hysterectomy, comorbidities, tobacco use, substance abuseuse 
disorders, certain pain conditions, and use of prescription any psychiatric medications use 
(Table 2). Our findings were similar to other studies that showed that these factors increase the 
risk of chronic opioid use after major cardiac, thoracic, abdominal and pelvic procedures, or 
specific surgeries, including cesarean delivery, hysterectomy, hip or knee arthroplasty, spine, or 
bariatric surgeries.5-17, 38, 39 Previous studies have reported that residing in the South or Midwest 
regions of the U.S. was associated with  prescription opioid abuse specifically among women. In 
our study, the risk of chronic opioid use after hysterectomy was also higher in the South, 
Midwest, and West compared with the Northeast.(Table 2) These findings underscore the 
importance of considering the individual patient’s pain management needs, and risk factors for 
opioid misuse at the time of opioid prescribing after hysterectomy and other surgical 
procedures, and importance of medical care, monitoring and follow-up post-operatively . 
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The literature describing the relationship between the initial opioid prescribing 
characteristics and the risk of chronic opioid use after hysterectomy among opioid naïve 
patients is limited. Prior observational studies have produced inconclusive results, which may be 
attributed to the study sample (inclusion of patients with minor surgical procedures) or small 
study sample size.11,38 Our results showed that initial opioid prescribing characteristics, including 
opioid type, daily dose, and duration of days’ supply were associated with chronic opioid use in 
the 6 months following hysterectomy among opioid naïve patients. The odds of chronic opioid 
use following initiation after hysterectomy were 3531% higher among patients starting 
hydrocodone compared to patients who began therapy with oxycodone even though prior 
research has demonstrated that oxycodone is associated with risk of addiction, morbidity and 
mortality.40-42 One explanation for this finding is that for many years hydrocodone was the most 
commonly prescribed opioid medication in the United States, in part because it was a schedule 
III drug during the study period and was considered to be lesser risk than schedule II opioids 
such as oxycodone, therefore, hydrocodone may have been prescribed more liberally, 
especially to patients with a higher tendency of opioid overuse, which is a possible confounding 
by contraindication. In August 21, 2014, the U.S. Drug Enforcement Administration (DEA) 
issued stricter prescribing requirements and moved hydrocodone-containing medications from a 
Schedule III to a Schedule II controlled substance.43 Notably, the initial opioid prescribing 
characteristics, such as longer days’ supply and higher daily morphine milligram equivalent 
dose, that were associated with post-operative chronic opioid use after hysterectomy, are also 
risk factors for opioid misuse and opioid-related mortality.44-47 By identifying modifiable risk 
factors for chronic opioid use after hysterectomy, such as pre-operative opioid prescribing, 
abdominal or laparoscopic/robotic hysterectomymode of hysterectomy, and characteristics of 
opioid prescribing after surgery, we may be able to develop strategies and interventions to 
decrease the likelihood of chronic opioid use.
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There is no standard definition for chronic opioid use after surgery. We selected the 
trajectory modeling approach because of its advantages over other methods for describing 
longitudinal trajectories and identifying patients who used opioids consistently over a longer 
duration.29,30 Traditional medication adherence measures, such as the proportion of days 
covered or the number of months of continuous medication use, may not distinguish between  
consistent users in follow-up periods or between patients who discontinue medication 
completely versus those who simply have a gap in use. The trajectory models repeatedly 
assess medication use throughout the entire follow-up period and summarize long-term 
medication adherence accounting for the time-varying nature of adherence.29 We found that 
0.91.38% of hysterectomy patients became chronic opioid users in the 6 months after surgery. 
Using Optum data from January 01, 2011 to December 31, 2014, Swenson et al. reported 0.5% 
(122 out of 24,331) of women who had a hysterectomy had new persistent opioid use following 
hysterectomy.5 In Swenson’s study, persistent opioid use in the 6 months post-hysterectomy 
was defined as a minimum of 2 opioid prescriptions in the 6 months post-surgery (one between 
15-90 days and one at least 91-180 days) and top quartile use (amount and duration).5 The 
difference in incidence of chronic use/new persistent use between these studies is attributable 
to the use of different definitions for chronic opioid use.
          Our findings suggest that prescribing lower doses for shorter days’ supply may reduce the 
risk of subsequent chronic opioid use, be a better strategy for post-surgical pain management, 
andwhich is consistent with the strategies published in guidelines advocated by multiple federal 
and state agencies, professional societies, and advocacy groups. Although specific guidelines 
differ in exact wording and specific recommendations, prescribing the lowest dose for the 
shortest amount of time and screening for substance use and opioid dependence are clearly 
defined themes across multiple guidelines.48-50 However, practice change solely on the basis of 
guidelines can be slow, and current evidence suggests that physicians are prescribing excess 
opioids to patients to control acute pain post-surgery at hospital discharge. Studies from the 
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surgical fields of urology, orthopedics, and obstetrics and gynecology have shown that 
physicians prescribe more than twice the amount of opioid medication patients actually 
consume post-discharge which adds up to millions of excess unused opioid tablets available for 
diversion and abuse.51-54 A recent study showed that among obstetricians and gynecologists, 
only 62% reported tailoring prescriptions to the individual patient and only 22% reported they 
performed an opioid dependence screen prior to prescribing.55 Improving adherence to best 
practices for opioid prescribing, including tailoring prescriptions to the individual patient’s pain 
management needs and risks of future opioid misuse and abuse, could play a major role in 
reducing the magnitude of the opioid epidemic. 
Limitations
First, the study subjects included in this study are commercially insured in the United 
States with 109% covered by Medicare Advantage (Table1). The demographic characteristics, 
clinical conditions, and opioid preoperative use patterns may differ from uninsured, Medicaid or 
Medicare covered populations. Thus, the study results might not be generalizable to patients 
enrolled in Medicaid or Medicare. with government covered insurances. 
Our study is subject to several limitations due to the nature of observational studies 
using claims data. Some important medical indications, such as severity of pain, which may be 
related to the hysterectomy procedure or underlying conditions leading to hysterectomy, were 
not captured in the data. Other unmeasured confounding factors included social and economic 
factors during follow up. The low prevalence of OUDs or methadone use excluded in figure 1, 
and other substance abuseuse disorders, tobacco use, and alcohol abuse presented in table 1 
might be due to poor sensitivity of ICD-9 diagnosis codes or CPT codes.  However, the impact 
may be non-differential if the unmeasured variables are similarly distributed in two comparison 
groups. 
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Opioid analgesics were assessed using pharmacy claims, which only captured opioid 
medications legally obtained and filled at outpatient pharmacies. The 69% prevalence of 
Patients not filling the initial opioid prescription post-hysterectomy may be attributed to either 
some patients not using opioids for post-surgical pain or to patients receiving their opioid 
prescription from an inpatient pharmacy.  The actual patterns of opioid use (actual consumption) 
was not measured and, based on prior studies, differs substantially from the amount of opioid 
medication prescribed. Furthermore, the result that hydrocodone has a higher risk of chronic 
use after hysterectomy compared to oxycodone could be due to a possible confounding by 
contraindication. 
The outcome assessed in this study was chronic opioid use during the first 6 months 
after hysterectomy. Although chronic opioid use within 6 months has been associated with 
opioid misuse and opioid-related death, it was not possible to differentiate whether patients 
persistently used opioids for 6 months as a legitimate treatment for pain control or because they 
became dependent upon opioids after their post-surgical pain had abated.use of the 
medications to treat acute pain.56 Additionally, it was not possible is impossible to determine 
know if the women were continuing to receive their opioid for the pain related to their 
hysterectomy or for other pain; the reason for the opioid prescription fills during this time 
periods;  It is possible that the reason for filling opioid prescriptions in the 6 months following 
hysterectomy was not for personal use but for diversion.57 Our findings that chronic opioid use 
post hysterectomy was significantly associated with preoperative opioid use and initial opioid 
prescribing could be due to complex relationships between chronic pain post-surgery, acute 
pain post-surgery, and chronic pain pre-surgery.
Conclusions
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In this study, About 0.87% ofapproximately 3 in 200 opioid naïve women appear to 
become chronic opioid users after hysterectomy. Besides commonly recognized demographic 
and clinical risk factors, chronic opioid use after hysterectomy was associated with initial opioid 
prescribing characteristics, such as longer days’ supply and higher daily opioid dose. Although 
prescription opioid medications provide effective analgesia after surgery, they must be used with 
caution given the potential risk for subsequent chronic opioid use that is associated with opioid 
misuse and overdose-related mortality. Our findings support the need to manage post-surgical 
pain with the least amount of opioid medication possible to effectively control a patient’s 
symptoms, and close clinical post-op follow-up for those patients who prescribed opioids.  
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Figure 1. Flow Chart of the Study Population.
N=157,934 patients had 
hysterectomy between 07/01/2010 
and 03/31/2015. 
N= 121,052 cancer free patients
Excluded 23,79518,202 patients 
with no opioid prescription fill within 
7 days of hysterectomy
N=135,748 patients had 
continuous enrollment
Excluded 22,186 patients without 
continuous enrollment for 6 
months prior to hysterectomy
Excluded 14,696 patients who had 
cancer diagnosis or radical 
hysterectomy
Excluded 43,30348,778 patients 
used prescription opioids and 232 
were diagnosed OUDs within 6 
months prior to hysterectomy. 
N=53,92454,045
Opioid naïve patients who 
received opioids within 7 days of 
hysterectomy
Final study cohort 
N=49,84450,127
Excluded 4,0803,918 patients who 
were missing important 
demographic data
Abdominal 
Hysterectomy
N=12,966 986 
(26%)
Laparoscopically 
assisted hysterectomy 
N= 29,409 640 (59%)
Vaginal 
hysterectomy 
N= 7,469 502 
(15%)
N=77,71972,247
Opioid naïve patients
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Figure 2. Trajectories of filling opioid prescriptions in 6 months post hysterectomy. The 
solid or dashed lines represent the distinct estimated opioid prescription filling 
trajectories. The dot symbols represent the mean estimated proportion in each 
trajectory group dispensed an opioid prescription at each month. These indicate the 
mean estimated probability of filling an opioid prescription for patients in each group at 
each time point. Overall counts and percentages of patients in each group are 
presented in the underneath table. Patients in trajectory 4 were classified as opioid 
chronic users. Patients in trajectories 1, 2, 3 were classified as opioid non-chronic 
users. The x-axis indicates each 30-day interval during the 6-month follow-up period, 
while the y-axis indicates the estimated proportion of patients filled a prescription opioid 
within each 30-day interval.
Trajectories Trajectory 1 Trajectory 2 Trajectory 3 Trajectory 4
N (%) 39,677 (79.15%) 3,304 (6.59%) 6,453 (12.87%) 693 (1.38%)
1 2 3 4 5 6
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Trajectory 1
Trajectory 2
Trajectory 3
Trajectory 4
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Non-chronic 
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Figure 2. Proportion in each trajectory group dispensed an opioid prescription in each 
month.
Trajectories 1 2 3 4
N (%) 2,808 (5.63%) 2,543(5.10%) 44,059 (88.39%) 434 (0.87%)
Table 1. Comparison of baseline patient characteristics among opioid-naïve 
patients who received prescription opioids within 7 days after hysterectomy, N=50,127
1 2 3 4 5 6
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Trajectory 1
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Patient characteristics Non-chronic 
Users†
(N=48,434)
Chronic Opioid Users‡
(N= 693)
P-value
Charlson Comorbidity Index, mean (95% CI) 1.60 (1.57, 1.64) 1.74 (1.45, 2.02) 0.3479
Length of stay in days, mean (95% CI) 2.32 (2.30, 2.35) 3.79 (3.39, 4.19) <0.0001
Age, years, mean (95% CI) 48.1 (48.0, 48.2) 49.8 (48.9,50.7) 0.0004
Age at hysterectomy, years
       <40
       40-49
       50+
9,100 (18.41) 
22,538 (45.59) 
17,796 (36.00)
126 (18.18)
255 (36.80) 
312 (45.02)
<.0001
Substance use and abuse, N (%)
      Tobacco
       Alcohol
       Other substance use disorders§
2,637 (5.33) 
177 (0.36) 
55 (0.11)
60 (8.66) 
9 (1.30) 
4 (0.58)
0.0001
 <.0001
0.0004
Psychiatric medications, N (%)
       Benzodiazepines
       Antidepressants
       Stimulants
4,201 (8.50) 
9,984 (20.20) 
767 (1.55)
125 (18.04) 
233 (33.62)
25 (3.61)
<.0001
< .0001
< .0001
Pain conditions, N (%)
       Fibromyalgia
       Headache syndromes
       Back pain
1,530 (3.10) 
4,019 (8.13)
4,659 (9.42)
30 (4.33) 
82 (11.83) 
110 (15.87)
0.0632
0 .0004
< .0001
Type of hysterectomy, N (%)
       Abdominal hysterectomy
       Vaginal hysterectomy     
        Laparoscopic/Robotic
12,757 (25.81) 
7,428 (15.03 
29,249 (59.17)
228 (32.90) 
74 (10.68) 
391 (56.42)
<.0001
Surgery setting, N (%)
       Inpatient
       Outpatient
19,805 (40.06) 
29,629 (59.94)
352 (50.79) 
341 (49.21)
<.0001
US census region, N (%)
       Midwest
       Northeast
       South
       West
13,705 (27.72) 
5,075 (10.27) 
23,642 (47.83) 
7,012 (14.18)
186 (26.84) 
66 (9.52) 
332 (47.91) 
109 (15.73)
0.6351
Insurance type, N (%)
       Commercial
       Medicare
45,107 (91.25) 
4,327 (8.75)
586 (84.56) 
107 (15.44)
< .0001
Type of health plan, N (%)
       Exclusive provider organization
       Health maintenance organization
       Point of service
       Others¶
5,990 (12.12) 
4,913 (9.94)
34,004 (68.79) 
4,527 (9.16)
70 (10.10) 
89 (12.84) 
449 (64.79) 
85 (12.27)
0.0008
Year of hysterectomy
      2010-2013  
      2014-2015
21,949 (44.40) 
27,485 (55.60)
287 (41.41) 
406 (58.59)
0.1161
Initial Opioid Prescription Characteristics
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Days’ supply, days 4.85 (4.82, 4.87) 5.12 (4.89, 5.34) 0.0205
Average daily MME, mg/day 54.7 (54.3, 55.0) 58.4 (54.6, 62.2) 0.0571
Type of Opioid, N(%)
       Hydrocodone
       Oxycodone
       Other
17,555 (35.51) 
27,434 (55.50) 
4,445 (8.99)
266 (38.38) 
354 (51.08) 
73 (10.53)
0.0553
Tertile MME, mg/day
        <=40
        40.5-58.9
        60.0+ 
16,154 (32.68) 
16,718 (33.82) 
16,562 (33.50)
219 (31.60) 
221 (31.89) 
253 (36.51)
0.2425
Days’ supply, days
        1-3
        4-7
        8+
15,667 (31.69) 
29,098 (58.86) 
4,669 (9.44)
193 (27.85) 
423 (61.04) 
77 (11.11)
0.0566
Abbreviation: MME=Morphine Milligram Equivalent
†Non-chronic users refer to patients in trajectory 1, 2, and 3 in Figure 2.  
‡Chronic Opioid users refer to patients in trajectory 4 in Figure 2.
§Other substance use includes cocaine, marijuana, anxiolytic, stimulant, hallucinogenic drugs, or abuse 
of unspecified drugs/medications. 
¶Others include Indemnity and Preferred provider organization.
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Table 2. Baseline and initial opioid prescription characteristics that predict chronic opioid 
use following hysterectomy among opioid naive patients, 2010-2015; N=50, 127
Characteristics Unadjusted OR (95% CI) Adjusted OR† (95% CI)
Age group, years
       40-49
       < 40
       ≥ 50
Ref.
1.22 (0.99, 1.52)
1.55 (1.31, 1.83)
Ref.
1.20 (0.97, 1.49)
1.37 (1.14 1.65)
Insurance type
       Commercial
       Medicare
Ref.
1.90 (1.55, 2.35)
Ref.
1.98 (1.37, 2.87
Type of health plan, N (%)
       Exclusive provider organization
       Health maintenance organization
       Point of service
       Others‡
Ref.
1.55 (1.13, 2.13)
1.13 (0.88, 1.46)
1.61 (1.17, 2.21)
Ref.
1.19 (0.84, 1.68)
1.10 (0.85, 1.42)
0.75 (0.48, 1.18)
Type of hysterectomy
       Vaginal hysterectomy 
       Laparoscopic/Robotic       
       Abdominal hysterectomy     
Ref.
1.79 (1.38, 2.34)
1.34 (1.05, 1.72)
Ref.
1.52 (1.16, 2.00)
1.40 (1.09, 1.80)
Year (2010-2013 vs 2014-2015) 1.13 (0.97, 1.32) 1.24 (1.06, 1.46)
Length of stay (days) 1.14 (1.11, 1.16) 1.12 (1.10, 1.15)
Charlson comorbidity index 1.18 (1.06, 1.31) 1.16 (1.04, 1.30)
Pain conditions
       Headache (Yes vs. No)      
       Back pain (Yes vs. No)
1.52 (1.20, 1.91)
1.81 (1.48, 2.23)
1.33 (1.04, 1.69)
1.57 (1.27, 1.94)
Substance use 
       Alcohol
       Tobacco
3.66 (1.87, 7.18)
1.68 (1.29, 2.20)
1.84 (0.91, 3.74)
1.47 (1.12, 1.93)
Psychiatric medications
       Antidepressants
       Benzodiazepines
       Psychostimulants
2.00 (1.71, 2.35)
2.37 (1.95, 2.88)
2.38 (1.58, 3.56)
1.71 (1.45, 2.03)
1.89 (1.54, 2.33)
1.84 (1.21, 2.80)
Initial Opioid Prescription Characteristics
Type of opioid
        Oxycodone
        Hydrocodone
        Other
Ref.
1.17 (1.00, 1.38)
1.27 (0.99, 1.64)
Ref.
1.31 (1.10, 1.57)
1.26 (0.96, 1.64)
Days’ supply, days
        ≤ 3
        4-7
        ≥ 8
Ref.
1.18 (0.99, 1.40)
1.34 (1.03, 1.75)
Ref.
1.28 (1.06, 1.54)
1.41 (1.05, 1.89)
Tertile MME, mg/day
        < 40
        40 -58.9
        ≥ 60.0
Ref.
0.98 (0.81, 1.18)
1.13 (0.94, 1.35)
Ref.
1.14 (0.93, 1.40)
1.43 (1.14, 1.79)
Abbreviation: MME=Morphine Milligram Equivalent
Adjusted model: c-statistic = 0.70; Hosmer-Lemeshow Goodness-of-fit Test: X2 =19.30, df=8, p=0.0133
Page 63 of 78
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
†Adjusted for baseline patient demographic and clinical characteristics listed in this table.
‡Others include Indemnity and Preferred provider organization.
Page 64 of 78
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Table 3. Distribution of possible indications for chronic opioid use during the 6-month 
follow-up period after hysterectomy: shown as N (%).
Possible indications All patients in 
cohort
(N = 50,127)
Non-chronic 
Users
(N = 49,434)
Chronic Opioid 
Users
(N = 693)
P-value
Chronic pancreatitis
Headache syndromes
Back pain
Fibromyalgia
Additional anesthetic 
procedures†
0
1
2
≥ 3
70 (0.14)
3,284 (6.55)
4,477 (8.93)
1,470 (2.93)
46,132 (92.03) 
3,310 (6.60) 
525 (1.05) 
160 (0.32)
63 (0.13)
3,196 (6.47)
4,287 (8.67) 
1,407 (2.85)
45,768 (92.58) 
3,099 (6.27) 
459 (0.93) 
108 (0.22)
7 (1.01)
88 (12.70)
190 (27.42)
63 (9.09)
364 (52.53) 
211 (30.45)
  66 (9.52)
52 (7.50)
<.0001
< .0001
< .0001
< .0001
< .0001
†Number of additional procedures requiring anesthesia. 
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Table 1. Comparison of baseline patient characteristics among opioid-naïve patients who 
received prescription opioids within 7 days after hysterectomy, N=49,844
Patient characteristics Non-chronic Users**
(N=49,410)
Chronic Opioid 
Users*
(N= 434)
P-value
Charlson Comorbidity Index, mean (95% CI) 0.4 (0.4, 0.4) 0.8 (0.7, 0.9) < .0001
Length of stay in days, mean (95% CI) 1.00 (1.00, 1.02) 2.19 (1.86, 2.51) <.0001
Age, years, mean (95% CI) 48.1 (48.0, 48.2) 50.5 (49.3, 51.7) <.0001
Age at hysterectomy, years
       <40
       40-49
       50+
9,245 (18.71)
22,461 (45.46)
17,704 (35.83)
84 (19.35)
141 (32.49)
209 (48.16)
<.0001
Substance use and abuse, N (%)
      Tobacco
       Alcohol
       Marijuana
       Cocaine
       Other substance abuse***
2,714 (5.49)
181 (0.37)
5 (0.01)
8 (0.02)
35 (0.07)
49 (11.29)
8 (1.84)
0 (0.00)
1 (0.23)
0 (0.0)
< .0001
 .0003
NA
0.08
NA
Psychiatric medications, N(%)
       Benzodiazepines
       Antidepressants
       Stimulants
4,403 (8.91)
10,331 (20.91)
766 (1.55)
87 (20.05)
159 (36.64)
18 (4.15)
<.0001
< .0001
< .0001
Pain conditions, N (%)
       Fibromyalgia
       Headache syndromes
       Back pain
1,692 (3.42)
4,212 (8.52
5,053 (10.23)
32 (7.37)
41 (9.45)
85 (19.59)
<.0001
0.49
< .0001
Type of hysterectomy, N (%)
       Abdominal hysterectomy
       Vaginal hysterectomy     
        Laparoscopic/Robotic
12,814 (25.93)
7,412 (15.00)
29,184 (59.06)
152 (35.02)
57 (13.13)
225 (51.84)
<.0001
US census region, N (%)
       Midwest
       Northeast
       South
       West
13,907 (28.15)
5,041 (10.20)
23,609 (47.78)
6,853 (13.87)
118 (27.19)
36 (8.29)
202 (46.54)
78 (17.97)
0.07
Insurance type, N (%)
       Commercial
       Medicare
44,966 (91.01)
4,444 (8.99)
354 (81.57)
80 (18.43)
< .0001
Type of health plan, N (%)
       Exclusive provider organization
       Health maintenance organization
       Point of service
       Others****
5,905 (11.95)
4,899 (9.91)
33,992 (68.80)
4,614 (9.31)
43 (9.91)
55 (12.67)
274 (63.13)
62 (14.29)
0.0004
Year of hysterectomy
      2010-2013  
      2014-2015
21,952 (44.43)
27,458 (55.57)
180 (41.47)
254 (58.53)
0.22
Initial Opioid Prescription Characteristics
Days’ supply, days 4.81 (4.78, 4.83) 5.44 (5.07, 5.80) < 0.0001
Average daily MME*****, mg/day 55.0 (54.7, 55.4) 61.1 (55.5, 66.8) 0.03
Type of Opioid, N(%)
       Hydrocodone 18,738 (37.92) 176 (40.55) 0.16
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       Oxycodone
       Other
27,332 (55.32)
3,340 (6.76)
222 (51.15)
36 (8.29)
Tertile MME*****, mg/day
        <=40
        40.5-58.9
        60.0+ 
16,964 (34.33)
15,794 (31.97)
16,652 (33.70)
140 (32.26)
124 (28.57)
170 (39.17)
0.05
Days’ supply, days
        1-3
        4-7
        8+
15,838 (32.05)
29,097 (58.89)
4,475 (9.06)
116 (26.73)
259 (59.68)
59 (13.59)
0.001
Note: 
* Chronic Opioid users refer to patients in trajectory 4 in Figure 2.
** Non-chronic users refer to patients in trajectory 1, 2, and 3 in Figure 2.  
*** Other substance use includes anxiolytic, stimulant, hallucinogenic drugs, or abuse of unspecified 
drugs/medications. 
**** Others including Indemnity and Preferred provider organization.
***** MME=Morphine Milligram Equivalent
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Table 2. Baseline and initial opioid prescription characteristics that predict chronic opioid 
use following hysterectomy among opioid naive patients, 2010-2015; N=49,844
Characteristics Unadjusted OR (95% CI) Adjusted OR* (95% CI)
Age group, years
       40-49
       < 40
       50+
Ref.
1.45 (1.10, 1.90)
1.88 (1.52, 2.33)
Ref.
1.42 (1.08, 1.87)
1.54 (1.22, 1.95)
US census region
       Northeast
       Midwest
       South
       West
Ref.
1.19 (0.82, 1.73)
1.20 (0.84, 1.71)
1.59 (1.07, 2.37)
Ref.
1.33 (0.91, 1.96)
1.31 (0.91, 1.88)
1.77 (1.18, 2.66)
Insurance type
       Commercial
       Medicare
Ref.
2.29 (1.79, 2.92)
Ref.
1.58 (1.19, 2.11)
Type of hysterectomy
       Vaginal hysterectomy 
       Laparoscopic/Robotic       
       Abdominal hysterectomy     
Ref.
1.00 (0.75, 1.34)
1.54 (1.14, 2.09)
Ref.
1.03 (0.77, 1.39)
1.35 (0.98, 1.87)
       Year (2010-2013 vs 2014-2015) 1.13 (0.93, 1.37) 1.27 (1.05, 1.56)
       Length of stay (days) 1.13 (1.11, 1.16) 1.10 (1.07, 1.13)
       Charlson comorbidity index 1.34 (1.26, 1.42) 1.18 (1.10, 1.26)
Pain conditions
       Fibromyalgia (Yes vs. No)      
       Back pain (Yes vs. No)
2.25 (1.56, 3.23)
2.14 (1.69, 2.72)
1.58 (1.08, 2.31)
1.70 (1.32, 2.18)
Substance use 
       Alcohol
       Tobacco
5.11 (2.50, 10.44)
2.19 (1.62, 2.96)
2.28 (1.06, 4.87) 
1.81 (1.33, 2.46)
Psychiatric medications
       Antidepressants
       Benzodiazepines
       Psychostimulants
2.19 (1.80, 2.66)
2.56 (2.02, 3.25)
2.75 (1.71, 4.43)
1.78 (1.44, 2.19)
1.94 (1.51, 2.49)
2.07 (1.26, 3.41)
Initial Opioid Prescription Characteristics
Type of opioid
        Oxycodone
        Hydrocodone
        Other
Ref.
1.15 (0.95, 1.41)
1.33 (0.93, 1.89)
Ref.
1.35 (1.07, 1.70)
1.37 (0.95, 1.97)
Days’ supply, days
        <=3
        4-7
        8+
Ref.
1.22 (0.96, 1.51)
1.80 (1.31, 2.47)
Ref.
            1.41 (1.11, 1.79)
2.04 (1.43, 2.90)
Tertile MME, mg/day
        <=40
        40.5-58.9
        60.0+
Ref.
0.95 (0.75, 1.21)
1.24 (0.99, 1.55)
Ref.
1.24 (0.95, 1.62)
1.70 (1.28, 2.26)
Adjusted model: c-statistic = 0.73; Hosmer-Lemeshow Goodness-of-fit Test: X2 =9.32, df=8, p=0.32
*: Adjusted for baseline patient demographic and clinical characteristics listed in this table.
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Table 3. Distribution of possible indications for chronic opioid use during the 6-month 
follow-up period after hysterectomy: shown as N (%).
Possible indications All patients in 
cohort
(N = 49,844)
Non-chronic 
Users
(N = 49,410)
Chronic 
Opioid Users
(N = 414)
P-value
Rheumatoid arthritis
Chronic pancreatitis
Sickle cell disease
Headache syndromes
Back pain
Fibromyalgia
Additional anesthetic 
procedures*
0
1
2
3+
6 (0.01)
73 (0.15)
7 (0.01)
3,373 (6.77)
4,652 (9.33)
1,588 (3.19)
45,840 (91.97)
3,316 (6.65)
524 (1.05)
164 (0.33)
6 (0.01)
67 (0.14)
7 (0.01)
3,311 (6.70)
4,511 (9.13)
1,548 (3.13)
45,621 (92.33)
3,177 (6.43)
479 (0.97)
133 (0.27)
0 (0.00)
6 (1.38)
0 (0.00)
62 (14.29)
141 (32.49)
40 (9.22)
219 (50.46)
139 (32.03)
  45 (10.37)
31 (7.14)
NA
<.0001
NA
< 0.0001
< 0.0001
< 0.0001
< 0.0001
Note: 
*: Number of additional procedures requiring anesthesia. 
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